



Datasheet for ABIN1169172

anti-IL-33 antibody



[Go to Product page](#)

4 Images

4 Publications

Overview

Quantity:	100 µg
Target:	IL-33 (IL33)
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Functional Studies (Func)

Product Details

Immunogen:	Recombinant human IL-33.
Clone:	IL33305B
Isotype:	IgG2a
Specificity:	Recognizes human IL-33.
Cross-Reactivity:	Human
No Cross-Reactivity:	Mouse (Murine)
Cross-Reactivity (Details):	Does not cross-react with mouse IL-33.
Sterility:	0.2 µm filtered

Target Details

Target:	IL-33 (IL33)
---------	--------------

Target Details

Alternative Name: IL-33 ([IL33 Products](#))

Background: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

UniProt: [O95760](#)

Pathways: [Production of Molecular Mediator of Immune Response](#)

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Preservative: Without preservative

Storage: 4 °C, -20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Expiry Date: 12 months

Publications

Product cited in: Terpos, Katodritou, Symeonidis, Zagouri, Gerofotis, Christopoulou, Gavriatopoulou, Christoulas, Ntanasis-Stathopoulos, Kourakli, Konstantinidou, Kastritis, Dimopoulos: "Effect of induction



therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma." in: **International journal of cancer**, Vol. 145, Issue 2, pp. 559-568, (2019) ([PubMed](#)).

Abdul Alim, Domeij-Arverud, Nilsson, Edman, Ackermann: "Achilles tendon rupture healing is enhanced by intermittent pneumatic compression upregulating collagen type I synthesis." in: **Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA**, Vol. 26, Issue 7, pp. 2021-2029, (2018) ([PubMed](#)).

Sansoni, Vernillo, Perego, Barbuti, Merati, Schena, La Torre, Banfi, Lombardi: "Bone turnover response is linked to both acute and established metabolic changes in ultra-marathon runners." in: **Endocrine**, Vol. 56, Issue 1, pp. 196-204, (2016) ([PubMed](#)).

Rubiś, Wiśniowska-Śmiałek, Biernacka-Fijałkowska, Rudnicka-Sosin, Wypasek, Kozanecki, Dziewięcka, Faltyn, Karabinowska, Khachatryan, Hlawaty, Leśniak-Sobelga, Kostkiewicz, Płazak, Podolec: "Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR." in: **Heart and vessels**, Vol. 32, Issue 6, pp. 714-725, (2016) ([PubMed](#)).

Krege, Lane, Harris, Miller: "PINP as a biological response marker during teriparatide treatment for osteoporosis." in: **Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA**, Vol. 25, Issue 9, pp. 2159-71, (2014) ([PubMed](#)).



ELISA

Image 1. Inhibition of binding of recombinant human IL-33 (hIL-33) to human ST2 (hST2) in vitro using anti-IL-33 (human), mAb (IL33305B) . An indirect competitive ELISA was performed as follows; 1) coat microtiter plate wells with hST2-Fc (10 ug/ml); 2) add 2 ug/ml of IL-33 with or without a hIL-33 mAb to the wells followed by washing; 3) add anti-FLAG HRP conjugated (1:2,000) to an enzyme; 4) after adding the TMB solution, incubate at RT in the dark for 20 minutes. Immediately read the plate at 450 nm.

Western Blotting

Image 2. Western blot analysis of human IL-33 using anti-IL-33 (human), mAb (IL33305B) at 1:2,000 dilution. 1). Recombinant human IL-33 (His tagged). 2). Recombinant human IL-33 (FLAG® -tagged). 3). Recombinant mouse IL-33 (FLAG® -tagged). 4). Other protein (His tagged, negative control).

Immunohistochemistry

Image 3. Immunohistochemical staining of human tissue using anti-IL-33 (human), mAb (IL33305B) at 1:100 dilution. A. Immunoperoxidase staining (cytoplasmic) of formalin-fixed, paraffin-embedded human heart (100x, brown colour). B. Isotype control with IgG2a (negative control).

Please check the [product details page](#) for more images. Overall 4 images are available for ABIN1169172.